Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wales to fund Lucentis

This article was originally published in Scrip

Executive Summary

Novartis's Lucentis (ranibizumab) will be available on the Welsh NHS for treating patients with wet age-related macular degeneration (AMD) in both eyes, Edwina Hart, the Welsh minister for health and social services, has announced. £5 million pounds of funding is to be made available for the treatment during the current financial year, she added. The minister also promised a review of all wet-AMD drugs currently undergoing clinical trials so that they may become NHS treatment options as soon as they are licensed. In addition, treatment protocols are to be "appraised and reappraised to ensure the service delivers the best outcomes for patients".





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts